0000899243-23-007265.txt : 20230306
0000899243-23-007265.hdr.sgml : 20230306
20230306211100
ACCESSION NUMBER: 0000899243-23-007265
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230302
FILED AS OF DATE: 20230306
DATE AS OF CHANGE: 20230306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Provost Jean-Claude
CENTRAL INDEX KEY: 0001960060
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36569
FILM NUMBER: 23710872
MAIL ADDRESS:
STREET 1: C/O LANTHEUS HOLDINGS, INC.
STREET 2: 201 BURLINGTON RD, SOUTH BUILDING
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lantheus Holdings, Inc.
CENTRAL INDEX KEY: 0001521036
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 352318913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 331 TREBLE COVE ROAD
CITY: NORTH BILLERICA
STATE: MA
ZIP: 01862
BUSINESS PHONE: 978 671-8001
MAIL ADDRESS:
STREET 1: 331 TREBLE COVE ROAD
CITY: NORTH BILLERICA
STATE: MA
ZIP: 01862
FORMER COMPANY:
FORMER CONFORMED NAME: Lantheus MI Holdings, Inc.
DATE OF NAME CHANGE: 20110517
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-02
0
0001521036
Lantheus Holdings, Inc.
LNTH
0001960060
Provost Jean-Claude
C/O LANTHEUS HOLDINGS, INC.
201 BURLINGTON ROAD, SOUTH BLDG
BEDFORD
MA
01730
0
1
0
0
Chief Medical Officer
Common Stock
2023-03-02
4
A
0
16359
0.00
A
20823
I
By Theranostics Consulting SAS
Stock Option (right to buy)
73.35
2023-03-02
4
A
0
9535
0.00
A
2033-03-02
Common Stock
9535
9535
I
By Theranostics Consulting SAS
Consists of 5,453 restricted stock units that vest in equal installments over a three-year period and 10,906 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The option vests in three equal annual installments beginning on March 2, 2024.
/s/ Eric Green, attorney-in-fact
2023-03-06